Body Protective Compound 157 is a synthetic 15-amino-acid peptide derived from a cytoprotective protein in human gastric juice. It is the most studied non-approved tissue-repair research peptide, with a substantial preclinical literature and no completed human clinical trials.
Research and educational reference only. Not medical advice, dosing guidance, or an offer for sale.
BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain (sequence: GEPPPGKPADDAGLV) derived from a protective protein (BPC) isolated from human gastric juice. It is not a fragment of any approved drug; it has no endogenous equivalent circulating in the body at pharmacological concentrations.
The compound entered the research literature primarily through work from a Croatian laboratory in the 1990s–2000s and has since generated a substantial body of rodent experiments across multiple tissue contexts. Its short sequence makes it inexpensive to synthesize, which partly explains its outsized presence in the non-approved research-peptide literature: accessible cost lowers the barrier for preclinical investigation.
It is not approved by the FDA or any major regulatory agency for any indication. It is prohibited by the World Anti-Doping Agency (WADA). Its status in the compounding pharmacy context has been contested.
None fully established in humans; based on cell culture and rodent experiments
VEGFR2 upregulation
Proposed to upregulate vascular endothelial growth factor receptor 2 (VEGFR2), promoting new-vessel formation and tissue vascularisation in wound models.
Nitric oxide (NO) pathway
Studies suggest modulation of endothelial nitric-oxide synthase (eNOS), with downstream effects on blood flow and cytoprotection.
Growth-factor pathway interactions
Reported interactions with PDGF, EGF, and GH-receptor signaling in cell models — contributing to fibroblast activation and ECM remodeling.
All completed studies are in cell or animal models
| Research context | Model | Reported finding | Evidence level |
|---|---|---|---|
| Tendon & ligament repair | Rodent (transection, crush) | Accelerated histological repair, tensile strength improvement | Preclinical |
| Gastrointestinal protection | Rodent ulcer & IBD models | Reduced ulcer area, mucosal cytoprotection | Preclinical |
| Muscle repair | Rodent crush & ischemia | Reduced fibrosis, improved strength recovery | Preclinical |
| Angiogenesis | Cell culture / rodent | VEGFR2 upregulation, new-vessel formation markers | Preclinical |
| Human clinical evidence | — | No controlled human trials completed | None |
Two distinct peptides frequently studied in overlapping contexts — different sequences, different mechanisms
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Source | Derived from human gastric juice protein | Active fragment of thymosin β4 |
| Sequence length | 15 amino acids | 7 amino acids |
| Primary mechanism | VEGFR2 / NO / growth-factor pathways | G-actin sequestration; cytoskeletal remodeling |
| Main research contexts | Tendon, GI, muscle | Wound healing, cardiac, hair follicle |
| Sport status | WADA-prohibited (S2 peptide hormones) | WADA-prohibited (S2) |
| FDA approval | None | None |
| Evidence level | Preclinical only | Preclinical only |
The two compounds are often compared because they appear in overlapping tissue-repair research contexts, but their sequences, targets, and proposed mechanisms are unrelated.
BPC-157’s 15-residue length places it at the short end of research peptides, making synthesis comparatively inexpensive. That accessibility is part of its appeal for preclinical researchers — but it is also precisely why the market carries a high proportion of low-quality material.
Short peptides require fewer coupling cycles but are not inherently pure. Common quality failures include truncation sequences (incomplete assembly), oxidation at methionine (if present in related analogs), and outright adulteration with filler. The only reliable quality check is a batch-specific certificate of analysis with identity confirmation by mass spectrometry and purity by reversed-phase HPLC — not an aggregate COA, not a manufacturer’s certificate applied to multiple lots.
How research peptides are synthesized and characterizedWhat is BPC-157?
BPC-157 (Body Protective Compound 157) is a synthetic 15-amino-acid peptide derived from a cytoprotective protein identified in human gastric juice. It is studied in preclinical models — primarily rodent and cell-culture — for tissue repair, GI protection, and angiogenesis. It has no FDA-approved medical use.
What is the proposed mechanism of action for BPC-157?
Several mechanisms have been proposed, none fully established in humans. The most cited involve upregulation of the VEGFR2 receptor (promoting angiogenesis), modulation of endothelial nitric-oxide synthase (eNOS), and interactions with PDGF and EGF signaling pathways. These are based on cell-culture and rodent experiments; the operative mechanism in humans, if any, is unknown.
What tissues and conditions has BPC-157 been studied in?
Preclinical research contexts include tendon and ligament repair (transection and crush models), gastrointestinal protection (ulcer and IBD models), skeletal muscle repair, and angiogenesis. There are no completed, controlled human clinical trials.
How does BPC-157 differ from TB-500?
BPC-157 and TB-500 are completely distinct peptides with unrelated mechanisms. BPC-157 (15 residues) is studied primarily through VEGFR2/NO pathways. TB-500 (7 residues, derived from thymosin β4) works through G-actin sequestration and cytoskeletal remodeling. Both are preclinical and not FDA-approved; both are prohibited in regulated sport.
Is BPC-157 banned in sport?
Yes — BPC-157 is prohibited by the World Anti-Doping Agency (WADA) under category S2 (Peptide Hormones and Related Substances). This is regardless of whether human efficacy has been established.
Why does synthesis quality matter for BPC-157?
At only 15 residues, BPC-157 is inexpensive to synthesize, which makes it easy to produce low-quality or adulterated material. The low cost is precisely why a batch-specific certificate of analysis (COA) — with identity confirmation by mass spectrometry and purity by HPLC — is essential for any research-grade supply.
What does the evidence base for BPC-157 look like overall?
The evidence base is almost entirely preclinical. Studies span multiple tissue contexts and consistently report positive findings in rodent models — which has driven significant research interest — but no controlled human clinical trials have been completed. The translation from rodent to human remains unproven, and any use in humans is outside approved medical practice.